Key Takeaways
- • Federal Circuit reverses district court judgment, reinstating Teva's patent claims covering methods of treating headaches using a genus of antagonistic anti-CGRP antibodies, finding them valid under both written description and enablement requirements.
- • Jury verdict of willful infringement stands: A jury had found Teva's method claims sufficiently described, enabled, and willfully infringed by Lilly; the district court's post-trial JMOL motion to invalidate those claims is now overturned on appeal.
- • Prior art establishes genus as well-known: The Federal Circuit accepted that anti-CGRP antibodies were well-established in the prior art, methods of antibody humanization were routine, and critically, all antibodies within the genus demonstrated efficacy in treating headaches—a finding that satisfied patent disclosure standards even with a single embodiment disclosure.
- • Significant implications for biotechnology patent litigation: The decision strengthens genus claims in the pharmaceutical sector, particularly for methods of treatment using established antibody classes, potentially shifting risk calculations in ongoing IP disputes between major drug manufacturers.
- • Lilly's IPR challenge partially unsuccessful: While the Patent Trial and Appeal Board agreed with Lilly that foundational anti-CGRP antibody patents were unpatentable, the board upheld method-of-treatment claims—a distinction now validated by the Federal Circuit's reversal.
Summary
The Federal Circuit has reversed a district court's judgment on a motion for judgment as a matter of law (JMOL) in a significant pharmaceutical patent dispute between Teva and Eli Lilly. The appellate decision validates Teva's patent claims covering methods of treating headaches by administering a genus of antagonistic anti-CGRP antibodies, finding that the claims satisfy both the written description and enablement requirements of patent law.
The dispute originated in district court where Teva asserted multiple patents against Lilly, including patents on anti-CGRP antibodies and methods of treatment using those antibodies. Lilly responded by challenging the patents through inter partes review (IPR) proceedings, arguing that anti-CGRP antibodies were well-established in the prior art with abundant exemplary disclosures. The Patent Trial and Appeal Board partially agreed, finding the foundational antibody patents unpatentable but upholding the method-of-treatment claims. The case then proceeded to trial on Teva's remaining method claims, where a jury found those claims both willfully infringed by Lilly and sufficiently described and enabled under patent law.
However, the district court subsequently issued a JMOL motion that invalidated the method claims despite the jury's findings. While the district court acknowledged that the jury could reasonably have concluded that anti-CGRP antagonist antibodies were well-known, that humanization methods were routine, and that all antibodies in the genus would treat headaches, the court nonetheless ruled the method claims invalid for lacking adequate written description and enablement.
The Federal Circuit's reversal fundamentally resets this analysis. The appellate court held that because the prior art demonstrated the genus was well-known, because methods of making the antibodies were routine, and critically because all antibodies within the genus functioned effectively in the claimed treatment method, even a single embodied disclosure satisfied patent law's disclosure requirements. This represents a meaningful standard for biotechnology patents, particularly for method claims utilizing established therapeutic classes where the genus characteristics are predictable and well-documented.
The decision carries material implications for ongoing pharmaceutical patent litigation. It reinforces that method-of-treatment claims can withstand validity challenges where the underlying therapeutic genus is established in the prior art and demonstrates consistent efficacy across the claimed population of compounds—a principle with broad application across the anti-CGRP therapeutic space and similar antibody-based treatments.
The dispute originated in district court where Teva asserted multiple patents against Lilly, including patents on anti-CGRP antibodies and methods of treatment using those antibodies. Lilly responded by challenging the patents through inter partes review (IPR) proceedings, arguing that anti-CGRP antibodies were well-established in the prior art with abundant exemplary disclosures. The Patent Trial and Appeal Board partially agreed, finding the foundational antibody patents unpatentable but upholding the method-of-treatment claims. The case then proceeded to trial on Teva's remaining method claims, where a jury found those claims both willfully infringed by Lilly and sufficiently described and enabled under patent law.
However, the district court subsequently issued a JMOL motion that invalidated the method claims despite the jury's findings. While the district court acknowledged that the jury could reasonably have concluded that anti-CGRP antagonist antibodies were well-known, that humanization methods were routine, and that all antibodies in the genus would treat headaches, the court nonetheless ruled the method claims invalid for lacking adequate written description and enablement.
The Federal Circuit's reversal fundamentally resets this analysis. The appellate court held that because the prior art demonstrated the genus was well-known, because methods of making the antibodies were routine, and critically because all antibodies within the genus functioned effectively in the claimed treatment method, even a single embodied disclosure satisfied patent law's disclosure requirements. This represents a meaningful standard for biotechnology patents, particularly for method claims utilizing established therapeutic classes where the genus characteristics are predictable and well-documented.
The decision carries material implications for ongoing pharmaceutical patent litigation. It reinforces that method-of-treatment claims can withstand validity challenges where the underlying therapeutic genus is established in the prior art and demonstrates consistent efficacy across the claimed population of compounds—a principle with broad application across the anti-CGRP therapeutic space and similar antibody-based treatments.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.